{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:35:11Z","timestamp":1787657711701,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"DOI":"10.1186\/s13065-024-01347-4","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T09:13:43Z","timestamp":1732612423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Molecular exploration of natural and synthetic compounds databases for promising hypoxia inducible factor (HIF) Prolyl-4- hydroxylase domain (PHD) inhibitors using molecular simulation and free energy calculations"],"prefix":"10.1186","volume":"18","author":[{"given":"Abrar Mohammad","family":"Sayaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kafila","family":"Kousar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Suleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah A.","family":"Albekairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdulRahman","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelali","family":"Agouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kar Kheng","family":"Yeoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"1347_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2022.463411","volume":"1679","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Screening of prolyl hydroxylase 2 inhibitors based on quantitative strategy of peptides. J Chromatogr A. 2022;1679: 463411.","journal-title":"J Chromatogr A"},{"issue":"11","key":"1347_CR2","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.1021\/acs.jmedchem.1c00415","volume":"64","author":"Y Wu","year":"2021","unstructured":"Wu Y, et al. Inhibition of the oxygen-sensing asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor: a potential hypoxia response modulating strategy. J Med Chem. 2021;64(11):7189\u2013209.","journal-title":"J Med Chem"},{"issue":"10","key":"1347_CR3","doi-asserted-by":"publisher","first-page":"16875","DOI":"10.18632\/oncotarget.15171","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8(10):16875.","journal-title":"Oncotarget"},{"issue":"2","key":"1347_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.yexcr.2017.03.008","volume":"356","author":"CW Pugh","year":"2017","unstructured":"Pugh CW, Ratcliffe PJ. New horizons in hypoxia signaling pathways. Exp Cell Res. 2017;356(2):116\u201321.","journal-title":"Exp Cell Res"},{"issue":"6","key":"1347_CR5","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","volume":"176","author":"RS Apte","year":"2019","unstructured":"Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248\u201364.","journal-title":"Cell"},{"issue":"5569","key":"1347_CR6","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1126\/science.1069372","volume":"296","author":"D Vion","year":"2002","unstructured":"Vion D, et al. Manipulating the quantum state of an electrical circuit. Science. 2002;296(5569):886\u20139.","journal-title":"Science"},{"issue":"6892","key":"1347_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nature00767","volume":"417","author":"W-C Hon","year":"2002","unstructured":"Hon W-C, et al. Structural basis for the recognition of hydroxyproline in HIF-1\u03b1 by pVHL. Nature. 2002;417(6892):975\u20138.","journal-title":"Nature"},{"issue":"2","key":"1347_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.yexcr.2017.05.004","volume":"356","author":"VH Haase","year":"2017","unstructured":"Haase VH. Therapeutic targeting of the HIF oxygen-sensing pathway: lessons learned from clinical studies. Exp Cell Res. 2017;356(2):160\u20135.","journal-title":"Exp Cell Res"},{"issue":"16","key":"1347_CR9","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1093\/emboj\/cdg392","volume":"22","author":"E Berra","year":"2003","unstructured":"Berra E, et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1\u03b1 in normoxia. EMBO J. 2003;22(16):4082\u201390.","journal-title":"EMBO J"},{"issue":"12","key":"1347_CR10","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1021\/acs.jmedchem.8b01596","volume":"62","author":"Z Li","year":"2019","unstructured":"Li Z, You Q, Zhang X. Small-molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications. J Med Chem. 2019;62(12):5725\u201349.","journal-title":"J Med Chem"},{"issue":"11","key":"1347_CR11","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011\u201322.","journal-title":"N Engl J Med"},{"key":"1347_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Vadadustat: first approval. Drugs. 2020;80:1365\u201371.","journal-title":"Drugs"},{"issue":"1","key":"1347_CR13","doi-asserted-by":"publisher","first-page":"20680","DOI":"10.1038\/s41598-022-24154-0","volume":"12","author":"MS Islam","year":"2022","unstructured":"Islam MS, et al. Structural analysis of the 2-oxoglutarate binding site of the circadian rhythm linked oxygenase JMJD5. Sci Rep. 2022;12(1):20680.","journal-title":"Sci Rep"},{"issue":"1","key":"1347_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1124\/jpet.122.001126","volume":"383","author":"A Zuk","year":"2022","unstructured":"Zuk A, et al. Preclinical characterization of vadadustat (AKB-6548), an oral small molecule hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia. J Pharmacol Exp Ther. 2022;383(1):11\u201324.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1347_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4155\/fmc.13.202","volume":"6","author":"F Schmidt","year":"2014","unstructured":"Schmidt F, et al. Predictive in silico off-target profiling in drug discovery. Future Med Chem. 2014;6(3):295\u2013317.","journal-title":"Future Med Chem"},{"issue":"7","key":"1347_CR16","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1039\/C6MD00240D","volume":"7","author":"Y Wu","year":"2016","unstructured":"Wu Y, et al. Small-molecule inhibitors of HIF-PHD2: a valid strategy to renal anemia treatment in clinical therapy. Medchemcomm. 2016;7(7):1271\u201384.","journal-title":"Medchemcomm"},{"issue":"3","key":"1347_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nrneph.2015.193","volume":"12","author":"PH Maxwell","year":"2016","unstructured":"Maxwell PH, Eckardt K-U. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat Rev Nephrol. 2016;12(3):157\u201368.","journal-title":"Nat Rev Nephrol"},{"key":"1347_CR18","doi-asserted-by":"publisher","first-page":"1202128","DOI":"10.3389\/fphar.2023.1202128","volume":"14","author":"AM Sayaf","year":"2023","unstructured":"Sayaf AM, et al. Exploring the natural products chemical space through molecular search to discover potential inhibitors to target Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Domain (PHD). Front Pharmacol. 2023;14:1202128.","journal-title":"Front Pharmacol"},{"issue":"30","key":"1347_CR19","doi-asserted-by":"publisher","first-page":"19470","DOI":"10.1039\/D2RA03281C","volume":"12","author":"AH Alkhzem","year":"2022","unstructured":"Alkhzem AH, Woodman TJ, Blagbrough IS. Design and synthesis of hybrid compounds as novel drugs and medicines. RSC Adv. 2022;12(30):19470\u201384.","journal-title":"RSC Adv"},{"key":"1347_CR20","doi-asserted-by":"crossref","unstructured":"Alamgir A, Alamgir A. Drugs: their natural, synthetic, and biosynthetic sources. Therapeutic use of medicinal plants and their extracts: Volume 1: Pharmacognosy. 2017: p. 105\u2013123.","DOI":"10.1007\/978-3-319-63862-1_4"},{"issue":"60","key":"1347_CR21","doi-asserted-by":"publisher","first-page":"38079","DOI":"10.1039\/D1RA07377J","volume":"11","author":"P Gopinath","year":"2021","unstructured":"Gopinath P, Kathiravan M. Docking studies and molecular dynamics simulation of triazole benzene sulfonamide derivatives with human carbonic anhydrase IX inhibition activity. RSC Adv. 2021;11(60):38079\u201393.","journal-title":"RSC Adv"},{"issue":"12","key":"1347_CR22","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1161\/ATVBAHA.107.148551","volume":"27","author":"M Nangaku","year":"2007","unstructured":"Nangaku M, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol. 2007;27(12):2548\u201354.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"1347_CR23","doi-asserted-by":"publisher","first-page":"13459","DOI":"10.1073\/pnas.192342099","volume":"99","author":"M Ivan","year":"2002","unstructured":"Ivan M, et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci. 2002;99(21):13459\u201364.","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"1347_CR24","doi-asserted-by":"publisher","first-page":"20551","DOI":"10.3390\/molecules201119717","volume":"20","author":"SY Kim","year":"2015","unstructured":"Kim SY, Yang EG. Recent advances in developing inhibitors for hypoxia-inducible factor prolyl hydroxylases and their therapeutic implications. Molecules. 2015;20(11):20551\u201368.","journal-title":"Molecules"},{"issue":"6","key":"1347_CR25","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1124\/mol.110.070508","volume":"79","author":"TD Barrett","year":"2011","unstructured":"Barrett TD, et al. Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor. Mol Pharmacol. 2011;79(6):910\u201320.","journal-title":"Mol Pharmacol"},{"key":"1347_CR26","unstructured":"Rose PW, et al. The RCSB protein data bank: integrative view of protein, gene and 3D structural information. Nucleic Acids Res. 2016: p. gkw1000."},{"issue":"4","key":"1347_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1007449","volume":"16","author":"Y Haddad","year":"2020","unstructured":"Haddad Y, Adam V, Heger Z. Ten quick tips for homology modeling of high-resolution protein 3D structures. PLoS Comput Biol. 2020;16(4): e1007449.","journal-title":"PLoS Comput Biol"},{"issue":"10","key":"1347_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078085","volume":"8","author":"F Ntie-Kang","year":"2013","unstructured":"Ntie-Kang F, et al. AfroDb: a select highly potent and diverse natural product library from African medicinal plants. PLoS ONE. 2013;8(10): e78085.","journal-title":"PLoS ONE"},{"issue":"1","key":"1347_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13321-020-00424-9","volume":"12","author":"M Sorokina","year":"2020","unstructured":"Sorokina M, Steinbeck C. Review on natural products databases: where to find data in 2020. J Cheminform. 2020;12(1):20.","journal-title":"J Cheminform"},{"issue":"1","key":"1347_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-2946-5-28","volume":"5","author":"H Kang","year":"2013","unstructured":"Kang H, et al. HIM-herbal ingredients in-vivo metabolism database. J Cheminform. 2013;5(1):1\u20136.","journal-title":"J Cheminform"},{"issue":"2","key":"1347_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/07391102.2020.1714480","volume":"39","author":"MK Teli","year":"2021","unstructured":"Teli MK, et al. In silico identification of hydantoin derivatives: a novel natural prolyl hydroxylase inhibitor. J Biomol Struct Dyn. 2021;39(2):703\u201317.","journal-title":"J Biomol Struct Dyn"},{"issue":"12","key":"1347_CR32","doi-asserted-by":"publisher","first-page":"e1004586","DOI":"10.1371\/journal.pcbi.1004586","volume":"11","author":"PA Ravindranath","year":"2015","unstructured":"Ravindranath PA, et al. AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility. PLoS Comput Biol. 2015;11(12):e1004586.","journal-title":"PLoS Comput Biol"},{"issue":"12","key":"1347_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004586","volume":"11","author":"PA Ravindranath","year":"2015","unstructured":"Ravindranath PA, et al. AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility. PLoS Comput Biol. 2015;11(12): e1004586.","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"1347_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/wcms.1298","volume":"7","author":"S Yuan","year":"2017","unstructured":"Yuan S, Chan HS, Hu Z. Using PyMOL as a platform for computational drug design. Wiley Interdiscip Rev Comput Mol Sci. 2017;7(2): e1298.","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"1347_CR35","unstructured":"Maestro S. Maestro. Schr\u00f6dinger, LLC, New York, NY, 2020. 2020."},{"issue":"2","key":"1347_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.31643\/2023\/6445.13","volume":"325","author":"KA Azzam","year":"2023","unstructured":"Azzam KA. SwissADME and pkCSM webservers predictors: an integrated online platform for accurate and comprehensive predictions for in silico ADME\/T properties of artemisinin and its derivatives. Kompleksnoe Ispolzovanie Mineralnogo Syra Complex use of mineral resources. 2023;325(2):14\u201321.","journal-title":"Kompleksnoe Ispolzovanie Mineralnogo Syra Complex use of mineral resources"},{"key":"1347_CR37","doi-asserted-by":"crossref","unstructured":"Pires DE, Kaminskas LM, Ascher DB. Prediction and optimization of pharmacokinetic and toxicity properties of the ligand. Computational drug discovery and design. 2018: p. 271\u2013284.","DOI":"10.1007\/978-1-4939-7756-7_14"},{"key":"1347_CR38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.3389\/fchem.2020.00726","volume":"8","author":"F Wu","year":"2020","unstructured":"Wu F, et al. Computational approaches in preclinical studies on drug discovery and development. Front Chem. 2020;8:726.","journal-title":"Front Chem"},{"issue":"16","key":"1347_CR39","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jcc.20290","volume":"26","author":"DA Case","year":"2005","unstructured":"Case DA, et al. The Amber biomolecular simulation programs. J Comput Chem. 2005;26(16):1668\u201388.","journal-title":"J Comput Chem"},{"issue":"20","key":"1347_CR40","doi-asserted-by":"publisher","first-page":"10096","DOI":"10.1063\/1.1808117","volume":"121","author":"DJ Price","year":"2004","unstructured":"Price DJ, Brooks CL III. A modified TIP3P water potential for simulation with Ewald summation. J Chem Phys. 2004;121(20):10096\u2013103.","journal-title":"J Chem Phys"},{"issue":"7","key":"1347_CR41","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE III. PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput. 2013;9(7):3084\u201395.","journal-title":"J Chem Theory Comput"},{"issue":"10","key":"1347_CR42","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1002\/prot.23106","volume":"79","author":"J Li","year":"2011","unstructured":"Li J, et al. The VSGB 2.0 model: a next generation energy model for high resolution protein structure modeling. Proteins Structure Function Bioinformatics. 2011;79(10):2794\u2013812.","journal-title":"Proteins Structure Function Bioinformatics"},{"key":"1347_CR43","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fmolb.2019.00159","volume":"6","author":"A Khan","year":"2020","unstructured":"Khan A, et al. Dynamics insights into the gain of flexibility by helix-12 in ESR1 as a mechanism of resistance to drugs in breast cancer cell lines. Front Mol Biosci. 2020;6:159\u2013159.","journal-title":"Front Mol Biosci"},{"key":"1347_CR44","doi-asserted-by":"crossref","unstructured":"Khan A, et al. Higher infectivity of the SARS-CoV-2 new variants is associated with K417N\/T, E484K, and N501Y mutants: an insight from structural data. J Cell Physiol. 2021; n\/a(n\/a).","DOI":"10.1002\/jcp.30367"},{"key":"1347_CR45","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ijbiomac.2022.01.059","volume":"200","author":"A Khan","year":"2022","unstructured":"Khan A, et al. The Omicron (B.1.1. 529) variant of SARS-CoV-2 binds to the hACE2 receptor more strongly and escapes the antibody response: insights from structural and simulation data. Int J Biol Macromol. 2022;200:438.","journal-title":"Int J Biol Macromol"},{"key":"1347_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104967","volume":"139","author":"AH Arshia","year":"2021","unstructured":"Arshia AH, et al. De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations. Comput Biol Med. 2021;139: 104967.","journal-title":"Comput Biol Med"},{"issue":"D1","key":"1347_CR47","doi-asserted-by":"publisher","first-page":"D1417","DOI":"10.1093\/nar\/gkab1013","volume":"50","author":"T Fu","year":"2022","unstructured":"Fu T, et al. VARIDT 2.0: structural variability of drug transporter. Nucleic Acids Res. 2022;50(D1):D1417-d1431.","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"1347_CR48","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1021\/acschemneuro.8b00059","volume":"9","author":"T Fu","year":"2018","unstructured":"Fu T, et al. Exploring the binding mechanism of metabotropic glutamate receptor 5 negative allosteric modulators in clinical trials by molecular dynamics simulations. ACS Chem Neurosci. 2018;9(6):1492\u2013502.","journal-title":"ACS Chem Neurosci"},{"key":"1347_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104692","volume":"136","author":"M Jomhori","year":"2021","unstructured":"Jomhori M, Mosaddeghi H, Farzin H. Tracking the interaction between single-wall carbon nanotube and SARS-Cov-2 spike glycoprotein: a molecular dynamics simulations study. Comput Biol Med. 2021;136: 104692.","journal-title":"Comput Biol Med"},{"issue":"5","key":"1347_CR50","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1021\/acschemneuro.7b00490","volume":"9","author":"W Xue","year":"2018","unstructured":"Xue W, et al. What contributes to serotonin-norepinephrine reuptake inhibitors\u2019 dual-targeting mechanism? The key role of transmembrane domain 6 in human serotonin and norepinephrine transporters revealed by molecular dynamics simulation. ACS Chem Neurosci. 2018;9(5):1128\u201340.","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"1347_CR51","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1021\/acschemneuro.1c00694","volume":"13","author":"W Xue","year":"2022","unstructured":"Xue W, et al. Molecular mechanism for the allosteric inhibition of the human serotonin transporter by antidepressant escitalopram. ACS Chem Neurosci. 2022;13(3):340\u201351.","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"1347_CR52","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.kint.2017.03.008","volume":"92","author":"S Kiriakidis","year":"2017","unstructured":"Kiriakidis S, et al. Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor. Kidney Int. 2017;92(4):900\u20138.","journal-title":"Kidney Int"},{"issue":"18","key":"1347_CR53","doi-asserted-by":"publisher","first-page":"6290S","DOI":"10.1158\/1078-0432.CCR-sup-040025","volume":"10","author":"WG Kaelin Jr","year":"2004","unstructured":"Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004;10(18):6290S-6295S.","journal-title":"Clin Cancer Res"},{"key":"1347_CR54","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","volume":"9","author":"GL Semenza","year":"2014","unstructured":"Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol. 2014;9:47\u201371.","journal-title":"Annu Rev Pathol"},{"issue":"16","key":"1347_CR55","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.2174\/0929867325666180313105949","volume":"26","author":"BL Zaric","year":"2019","unstructured":"Zaric BL, et al. Homocysteine and hyperhomocysteinaemia. Curr Med Chem. 2019;26(16):2948\u201361.","journal-title":"Curr Med Chem"},{"issue":"3","key":"1347_CR56","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1124\/jpet.117.242503","volume":"363","author":"JL Ariazi","year":"2017","unstructured":"Ariazi JL, et al. Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor\u2013prolyl hydroxylase inhibitor for anemia. J Pharmacol Exp Ther. 2017;363(3):336\u201347.","journal-title":"J Pharmacol Exp Ther"},{"key":"1347_CR57","doi-asserted-by":"publisher","first-page":"1202128","DOI":"10.3389\/fphar.2023.1202128","volume":"14","author":"AM Sayaf","year":"2023","unstructured":"Sayaf AM, et al. Exploring the natural products chemical space through a molecular search to discover potential inhibitors that target the hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD). Front Pharmacol. 2023;14:1202128.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1347_CR58","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s11224-022-02012-z","volume":"33","author":"J Chandrasekaran","year":"2022","unstructured":"Chandrasekaran J, Balasubramaniam J. A computational evaluation of FDA medicines\u2019 ability to inhibit hypoxia-inducible factor prolyl hydroxylase-2 (PHD-2) for acute respiratory distress syndrome. Struct Chem. 2022;33(5):1391\u2013407.","journal-title":"Struct Chem"},{"issue":"2","key":"1347_CR59","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/cbdd.13640","volume":"95","author":"Z Yu","year":"2020","unstructured":"Yu Z, et al. Discovery of prolyl hydroxylase 2 inhibitors with new chemical scaffolds as in vivo active erythropoietin inducers through a combined virtual screening strategy. Chem Biol Drug Des. 2020;95(2):270\u20138.","journal-title":"Chem Biol Drug Des"},{"issue":"5","key":"1347_CR60","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.3390\/ijms24054710","volume":"24","author":"GF Camagni","year":"2023","unstructured":"Camagni GF, Minervini G, Tosatto SCE. Structural characterization of hypoxia inducible factor \u03b1-prolyl hydroxylase domain 2 interaction through MD simulations. Int J Mol Sci. 2023;24(5):4710.","journal-title":"Int J Mol Sci"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-024-01347-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-024-01347-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-024-01347-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T10:05:57Z","timestamp":1732615557000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-024-01347-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1347"],"URL":"https:\/\/doi.org\/10.1186\/s13065-024-01347-4","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"14 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}